Ponsegromab Promotes Weight Gain for Cancer Cachexia

The monoclonal antibody ponsegromab, which inhibits the cytokine GDF-15, led to improvements in weight gain, appetite, and physical activity compared to placebo in patients with cancer cachexia across multiple cancer types and in all dose groups. The findings suggest that GDF-15 is heavily involved in cachexia, and that ponsegromab is a promising therapeutic avenue for treating it.